Free Trial
NASDAQ:FLGT

Fulgent Genetics (FLGT) Stock Price, News & Analysis

Fulgent Genetics logo
$19.55 -0.03 (-0.15%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$19.42 -0.13 (-0.64%)
As of 08:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Fulgent Genetics Stock (NASDAQ:FLGT)

Key Stats

Today's Range
$19.38
$19.96
50-Day Range
$18.56
$21.81
52-Week Range
$14.57
$25.11
Volume
219,928 shs
Average Volume
286,216 shs
Market Capitalization
$595.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00
Consensus Rating
Moderate Buy

Company Overview

Fulgent Genetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

FLGT MarketRank™: 

Fulgent Genetics scored higher than 73% of companies evaluated by MarketBeat, and ranked 269th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fulgent Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Fulgent Genetics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Fulgent Genetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Fulgent Genetics are expected to decrease in the coming year, from ($0.85) to ($1.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fulgent Genetics is -14.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fulgent Genetics is -14.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Fulgent Genetics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Fulgent Genetics' valuation and earnings.
  • Percentage of Shares Shorted

    8.41% of the float of Fulgent Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulgent Genetics has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in Fulgent Genetics has recently increased by 2.48%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Fulgent Genetics does not currently pay a dividend.

  • Dividend Growth

    Fulgent Genetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.41% of the float of Fulgent Genetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulgent Genetics has a short interest ratio ("days to cover") of 4.8.
  • Change versus previous month

    Short interest in Fulgent Genetics has recently increased by 2.48%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Fulgent Genetics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Fulgent Genetics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 9 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,812.00 in company stock.

  • Percentage Held by Insiders

    31.76% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fulgent Genetics' insider trading history.
Receive FLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

FLGT Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Fulgent Genetics, Inc. (FLGT) - Yahoo Finance
See More Headlines

FLGT Stock Analysis - Frequently Asked Questions

Fulgent Genetics' stock was trading at $18.47 at the beginning of the year. Since then, FLGT stock has increased by 5.8% and is now trading at $19.55.

Fulgent Genetics, Inc. (NASDAQ:FLGT) issued its earnings results on Friday, May, 2nd. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.22. The business's quarterly revenue was up 14.0% on a year-over-year basis.
Read the conference call transcript
.

Fulgent Genetics subsidiaries include Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC.

Fulgent Genetics (FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Meta Platforms (META), Advanced Micro Devices (AMD), PayPal (PYPL), Broadcom (AVGO) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/02/2025
Today
7/11/2025
Next Earnings (Estimated)
8/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Healthcare
Current Symbol
NASDAQ:FLGT
CIK
1674930
Employees
1,313
Year Founded
2011

Price Target and Rating

High Price Target
$25.00
Low Price Target
$23.00
Potential Upside/Downside
+22.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.33)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$42.71 million
Net Margins
-13.94%
Pretax Margin
-16.93%
Return on Equity
-2.19%
Return on Assets
-2.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.32
Quick Ratio
6.32

Sales & Book Value

Annual Sales
$283.47 million
Price / Sales
2.10
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$36.92 per share
Price / Book
0.53

Miscellaneous

Outstanding Shares
30,440,000
Free Float
20,775,000
Market Cap
$595.10 million
Optionable
Optionable
Beta
1.03

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:FLGT) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners